Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study

Ulotaront, a trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptors agonist, has demonstrated efficacy in the treatment of patients with an acute exacerbation of schizophrenia in a 4-week, double-blind, placebo-controlled study. The aim of this 26-week open-label extension study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Correll, Christoph U., Koblan, Kenneth S., Hopkins, Seth C., Li, Yan, Heather Dworak, Goldman, Robert, Loebel, Antony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660889/
https://www.ncbi.nlm.nih.gov/pubmed/34887427
http://dx.doi.org/10.1038/s41537-021-00190-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660889/
https://www.ncbi.nlm.nih.gov/pubmed/34887427
http://dx.doi.org/10.1038/s41537-021-00190-z

Ejemplares similares